Fresenius Medical Care AG & Co. (NYSE:FMS) – Stock analysts at SunTrust Banks decreased their Q1 2019 earnings per share estimates for shares of Fresenius Medical Care AG & Co. in a research note issued to investors on Monday, November 19th. SunTrust Banks analyst D. Macdonald now expects that the company will post earnings per share of $0.57 for the quarter, down from their prior forecast of $0.61. SunTrust Banks currently has a “Buy” rating and a $46.00 target price on the stock. SunTrust Banks also issued estimates for Fresenius Medical Care AG & Co.’s Q2 2019 earnings at $0.63 EPS, Q3 2019 earnings at $0.68 EPS, Q4 2019 earnings at $0.73 EPS, FY2019 earnings at $2.61 EPS and FY2020 earnings at $2.84 EPS.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its earnings results on Tuesday, October 30th. The company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.11. The company had revenue of $4.72 billion for the quarter. Fresenius Medical Care AG & Co. had a return on equity of 10.87% and a net margin of 11.71%.

Several other analysts have also weighed in on FMS. Zacks Investment Research reissued a “hold” rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday, November 13th. TheStreet lowered Fresenius Medical Care AG & Co. from a “b-” rating to a “c+” rating in a research note on Monday, November 12th. Royal Bank of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday, July 31st. DZ Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, August 6th. Finally, ValuEngine lowered Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $62.00.

Fresenius Medical Care AG & Co. stock opened at $37.53 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 1.00 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $23.91 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 1.73 and a beta of 1.10. Fresenius Medical Care AG & Co. has a fifty-two week low of $37.47 and a fifty-two week high of $57.94.

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC acquired a new stake in Fresenius Medical Care AG & Co. in the 2nd quarter worth about $106,000. Destination Wealth Management acquired a new stake in Fresenius Medical Care AG & Co. in the 2nd quarter worth about $158,000. Mount Yale Investment Advisors LLC purchased a new position in shares of Fresenius Medical Care AG & Co. in the 2nd quarter worth about $192,000. Intercontinental Wealth Advisors LLC purchased a new position in shares of Fresenius Medical Care AG & Co. in the 2nd quarter worth about $203,000. Finally, HBK Sorce Advisory LLC purchased a new position in shares of Fresenius Medical Care AG & Co. in the 3rd quarter worth about $209,000. 2.53% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

Featured Article: How can you know how many shares are floating?

Earnings History and Estimates for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.